Enveric reports Q2 2026 results, advances EB-003 toward IND filing
The company said it continued IND-enabling work on its lead candidate EB-003 and reported preclinical data supporting a non-hallucinogenic profile ahead of a planned Phase 1 trial.
SEC filing